Experimental cancer combo shows early promise, but trial halted
NCT ID NCT05147272
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a new oral drug (RP-6306) combined with the chemotherapy gemcitabine in 67 adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check safety, find the best dose, and see if the combination could shrink tumors. The trial was terminated early, so final results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RP-6306 (a PKMYT1 inhibitor) combined with gemcitabine
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This was a very early (Phase 1) trial that was terminated, so results are limited. The combination may cause significant side effects, and it is unclear if it will work for most patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
# 1004, Memorial Sloan Kettering Cancer Institute
New York, New York, 10065, United States
-
# 1008, Columbia University
New York, New York, 10032, United States
-
# 1010, University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
# 1016, Mayo Clinic
Rochester, Minnesota, 55902, United States
-
# 1017, Mayo Clinic
Jacksonville, Florida, 32224, United States
-
# 1018, Mayo Clinic
Phoenix, Arizona, 85054, United States
-
# 1019, UCLA, Westwood Cancer Center
Los Angeles, California, 90095, United States
-
# 1022, Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
# 1023, START Midwest
Grand Rapids, Michigan, 49546, United States
-
# 2001, Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2C1, Canada
-
# 3003, Sarah Cannon Research Institute
London, United Kingdom